Benefit VA: Assessing the benefit of venetoclax addition in veterans with CLL/SLL responding to BTK inhibitor therapy

Authors

Thomas D. Rodgers (ORCID: https://orcid.org/0000-0002-8937-8231)
Suman Kambhampati (ORCID: https://orcid.org/0000-0002-8527-1365)
Mary R Nittala (ORCID: https://orcid.org/0000-0002-9755-5672)
Jesse D. Troy (ORCID: https://orcid.org/0000-0001-5410-8146)
Kenute Myrie
Manali Indravadan Patel (ORCID: https://orcid.org/0000-0002-9943-5762)
Daphne R. Friedman (ORCID: https://orcid.org/0000-0002-2938-5704)
Solomon A. Graf (ORCID: https://orcid.org/0000-0002-9475-3016)
Gerald C Hsu

Institutions

San Francisco VA Medical Center (US)
Occupational Safety & Health Administration (US)
University of Kansas (US)
University of Puget Sound (US)
Duke University (US)
University of California, San Francisco (US)
Durham University (GB)
University of Washington (US)
VA Palo Alto Health Care System (US)
The University of Kansas Health System (US)
Palo Alto Veterans Institute for Research (US)
VA Puget Sound Health Care System (US)
Durham VA Health Care System (US)
Kansas City VA Medical Center (US)
Seattle University (US)
University of San Francisco (US)
Stanford University (US)

Publication Details

Journal: Blood
Published: 2025-11-03
DOI: https://doi.org/10.1182/blood-2025-5692
Primary Topic: Chronic Lymphocytic Leukemia Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Benefit VA: Assessing the benefit of venetoclax addition in veterans with CLL/SLL responding to BTK inhibitor therapy

Thomas D. Rodgers, Suman Kambhampati, Mary R Nittala, Jesse D. Troy et al.

Nov 3, 2025

Blood

Chronic Lymphocytic Leukemia Research

article

Benefit VA: Assessing the benefit of venetoclax addition in veterans with CLL/SLL responding to BTK inhibitor therapy

Thomas D. Rodgers, Suman Kambhampati, Mary R Nittala, Jesse D. Troy, Kenute Myrie, Manali Indravadan Patel, Daphne R. Friedman, Solomon A. Graf, Gerald C Hsu

November 3, 2025article en

Abstract

No abstract available for this paper.

BloodVol. 146(Supplement 1)

San Francisco VA Medical Center (US), Occupational Safety & Health Administration (US), University of Kansas (US), University of Puget Sound (US), Duke University (US), University of California, San Francisco (US), Durham University (GB), University of Washington (US), VA Palo Alto Health Care System (US), The University of Kansas Health System (US), Palo Alto Veterans Institute for Research (US), VA Puget Sound Health Care System (US), Durham VA Health Care System (US), Kansas City VA Medical Center (US), Seattle University (US), University of San Francisco (US), Stanford University (US)

Openalex Percentile: Top 45%

Chronic Lymphocytic Leukemia Research

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Benefit VA: Assessing the benefit of venetoclax addition in veterans with CLL/SLL responding to BTK inhibitor therapy — Thomas D. Rodgers, Suman Kambhampati, et al. · Blood (2025) | TGRS Research Map | TGRS